Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a company specializing in targeted radiotherapies, has reported promising preclinical results for its novel prostate cancer treatment candidate, ATNM-400. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting, indicate that ATNM-400 may offer a new therapeutic option for prostate cancer patients, particularly those with metastatic castration-resistant prostate cancer (mCRPC) who have progressed following treatment with Pluvicto. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 9.14, holding more cash than debt on its balance sheet, which provides important runway for its development programs.
ATNM-400, which targets a distinct non-PSMA receptor that remains highly expressed even after Pluvicto therapy, has shown a 99.8% tumor growth inhibition in prostate cancer models with a single 40 µCi/kg dose. This suggests a potential for ATNM-400 to be considered as an alternative treatment. The receptor targeted by ATNM-400 is notably persistent in mCRPC patients, and the therapy leverages the alpha-particle emitter Ac-225, which has been demonstrated to cause lethal double-stranded DNA breaks.
The preclinical studies showed that ATNM-400 provided a statistically significant reduction in tumor volume compared to Pluvicto. Moreover, in mice with Pluvicto-resistant tumors, ATNM-400 exhibited robust antitumor activity when administered after Pluvicto treatment ceased to be effective. The treatment was well tolerated in the studies, with no apparent toxicities at two different dose levels and efficient clearance from essential organs.
Actinium’s Chairman and CEO, Sandesh Seth, expressed excitement about the data, highlighting the significant unmet need for therapies to address patients who progress after being treated with Pluvicto. Seth anticipates further validation of ATNM-400’s potential with additional data expected later in the year. The company’s stock, which has seen significant volatility with a 52-week range of $1.03 to $10.24, appears undervalued according to InvestingPro Fair Value metrics. Investors seeking detailed analysis can access 12 additional ProTips and comprehensive financial metrics through an InvestingPro subscription.
While these findings are encouraging, they are based on preclinical models, and further research is required to determine the efficacy and safety of ATNM-400 in humans. Actinium Pharmaceuticals is advancing the development of ATNM-400 and plans to provide more data as the research progresses. Investors should note that the company’s next earnings report is scheduled for May 12, 2025, which could provide additional insights into the development timeline and financial outlook.
This news article is based on a press release statement from Actinium Pharmaceuticals, Inc.
In other recent news, Actinium Pharmaceuticals has announced promising preclinical results for its prostate cancer treatment, ATNM-400, showing a 99.8% tumor growth inhibition in models. This novel therapy, which targets cancer cells differently from existing treatments, is set to be presented at the American Association for Cancer Research Annual Meeting in 2025. Actinium is also advancing its clinical pipeline, with data expected from trials targeting myeloid malignancies and solid tumors in the second half of 2025. The company has secured a supply of the radioisotope Actinium-225 to support these trials, highlighting its readiness for further clinical advancements. Analysts at H.C. Wainwright have maintained a Buy rating on Actinium, citing positive feedback from key opinion leaders and a strong financial position. Actinium’s Actimab-A therapy has shown positive outcomes in a clinical trial for acute myeloid leukemia, with a median overall survival of 18.4 months in patients. The company is preparing for a Phase 2/3 trial to further evaluate Actimab-A’s efficacy in relapsed or refractory AML patients. Actinium’s strategic focus on targeted radiotherapies and its robust patent portfolio underscore its commitment to addressing high unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.